Activators of the Anticipatory Unfolded Protein Response with Enhanced Selectivity for Estrogen Receptor Positive Breast Cancer

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2022 Jan 26

PMID 35080871

Authors

Matthew W Boudreau

Michael P Mulligan

David J Shapiro

Timothy M Fan

Paul J Hergenrother

Affiliations

Soon will be listed here.

Abstract

Approximately 75% of breast cancers are estrogen receptor alpha-positive (ERα+), and targeting ERα directly with ERα antagonists/degraders or indirectly with aromatase inhibitors is a successful therapeutic strategy. However, such treatments are rarely curative and development of resistance is universal. We recently reported , a compound that induces ERα-dependent cancer cell death through a mechanism distinct from clinically approved ERα drugs, via hyperactivation of the anticipatory unfolded protein response. has remarkable tumor-eradicative activity in multiple ERα+ tumor models. While has promise as a new drug, it has effects on ERα-negative (ERα-) cells in certain contexts. Herein, we construct modified versions of and identify variants with enhanced differential activity between ERα+ and ERα- cells. We report , a compound that maintains antitumor efficacy, has enhanced selectivity for ERα+ cancer cells, and is well tolerated in rodents. and related compounds represent an intriguing new class for the treatment of ERα+ cancers.

Citing Articles

Single Dose of a Small Molecule Leads to Complete Regressions of Large Breast Tumors in Mice.

Mulligan M, Boudreau M, Bouwens B, Lee Y, Carrell H, Zhu J ACS Cent Sci. 2025; 11(2):228-238.

PMID: 40028352 PMC: 11869136. DOI: 10.1021/acscentsci.4c01628.

Raptinal: a powerful tool for rapid induction of apoptotic cell death.

Smith A, Hergenrother P Cell Death Discov. 2024; 10(1):371.

PMID: 39164225 PMC: 11335860. DOI: 10.1038/s41420-024-02120-1.

Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy-Induced Necrosis.

Ghosh S, Yang R, Duraki D, Zhu J, Kim J, Jabeen M Cancer Res. 2023; 83(18):3115-3130.

PMID: 37522838 PMC: 10635591. DOI: 10.1158/0008-5472.CAN-23-0157.

Revisiting Estrogen for the Treatment of Endocrine-Resistant Breast Cancer: Novel Therapeutic Approaches.

Shete N, Calabrese J, Tonetti D Cancers (Basel). 2023; 15(14).

PMID: 37509308 PMC: 10377916. DOI: 10.3390/cancers15143647.

Evolution of 3-(4-hydroxyphenyl)indoline-2-one as a scaffold for potent and selective anticancer activity.

Boudreau M, Hergenrother P RSC Med Chem. 2022; 13(6):711-725.

PMID: 35814932 PMC: 9215341. DOI: 10.1039/d2md00110a.

References

Johnson T, Gallego R, Edwards M . Lipophilic Efficiency as an Important Metric in Drug Design. J Med Chem. 2018; 61(15):6401-6420. DOI: 10.1021/acs.jmedchem.8b00077. View

Andruska N, Zheng X, Yang X, Mao C, Cherian M, Mahapatra L . Estrogen receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression. Proc Natl Acad Sci U S A. 2015; 112(15):4737-42. PMC: 4403155. DOI: 10.1073/pnas.1403685112. View

Kaklamani V, Gradishar W . Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer. Oncologist. 2017; 22(5):507-517. PMC: 5423509. DOI: 10.1634/theoncologist.2015-0464. View

Di L, Rong H, Feng B . Demystifying brain penetration in central nervous system drug discovery. Miniperspective. J Med Chem. 2012; 56(1):2-12. DOI: 10.1021/jm301297f. View

Testa A, Lucas X, Castro G, Chan K, Wright J, Runcie A . 3-Fluoro-4-hydroxyprolines: Synthesis, Conformational Analysis, and Stereoselective Recognition by the VHL E3 Ubiquitin Ligase for Targeted Protein Degradation. J Am Chem Soc. 2018; 140(29):9299-9313. PMC: 6430500. DOI: 10.1021/jacs.8b05807. View

Lin X, Xiang H, Luo G . Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance. Eur J Med Chem. 2020; 206:112689. DOI: 10.1016/j.ejmech.2020.112689. View

Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andre F . 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol. 2018; 29(8):1634-1657. PMC: 7360146. DOI: 10.1093/annonc/mdy192. View

Partridge A, LaFountain A, Mayer E, Taylor B, Winer E, Asnis-Alibozek A . Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008; 26(4):556-62. DOI: 10.1200/JCO.2007.11.5451. View

Norinder U, Haeberlein M . Computational approaches to the prediction of the blood-brain distribution. Adv Drug Deliv Rev. 2002; 54(3):291-313. DOI: 10.1016/s0169-409x(02)00005-4. View

10.

Pollock J, Borkin D, Lund G, Purohit T, Dyguda-Kazimierowicz E, Grembecka J . Rational Design of Orthogonal Multipolar Interactions with Fluorine in Protein-Ligand Complexes. J Med Chem. 2015; 58(18):7465-74. PMC: 4584387. DOI: 10.1021/acs.jmedchem.5b00975. View

11.

Peh J, Boudreau M, Smith H, Hergenrother P . Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation. Cell Chem Biol. 2018; 25(8):996-1005.e4. PMC: 6097934. DOI: 10.1016/j.chembiol.2018.05.008. View

12.

Gillis E, Eastman K, Hill M, Donnelly D, Meanwell N . Applications of Fluorine in Medicinal Chemistry. J Med Chem. 2015; 58(21):8315-59. DOI: 10.1021/acs.jmedchem.5b00258. View

13.

Zbieg J, Liang J, Li J, Blake R, Chang J, Friedman L . Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer. Bioorg Med Chem Lett. 2021; 50:128335. DOI: 10.1016/j.bmcl.2021.128335. View

14.

Uddin M, Reignier S, Coulter T, Montalbetti C, Granas C, Butcher S . Syntheses and antiproliferative evaluation of oxyphenisatin derivatives. Bioorg Med Chem Lett. 2007; 17(10):2854-7. DOI: 10.1016/j.bmcl.2007.02.060. View

15.

Wu G, Zhao T, Kang D, Zhang J, Song Y, Namasivayam V . Overview of Recent Strategic Advances in Medicinal Chemistry. J Med Chem. 2019; 62(21):9375-9414. DOI: 10.1021/acs.jmedchem.9b00359. View

16.

Razavi P, Chang M, Xu G, Bandlamudi C, Ross D, Vasan N . The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 2018; 34(3):427-438.e6. PMC: 6327853. DOI: 10.1016/j.ccell.2018.08.008. View

17.

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

18.

Puyang X, Furman C, Zheng G, Wu Z, Banka D, Aithal K . Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα and ERα Breast Cancer. Cancer Discov. 2018; 8(9):1176-1193. DOI: 10.1158/2159-8290.CD-17-1229. View

19.

El-Ahmad Y, Tabart M, Halley F, Certal V, Thompson F, Filoche-Romme B . Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of.... J Med Chem. 2019; 63(2):512-528. DOI: 10.1021/acs.jmedchem.9b01293. View

20.

Kaplowitz N . Avoiding idiosyncratic DILI: two is better than one. Hepatology. 2013; 58(1):15-7. DOI: 10.1002/hep.26295. View